Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating...

Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver...

Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of...